Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Lisata Therapeutics ( (LSTA) ).
Lisata Therapeutics is advancing its proprietary technology, Certepetide, designed to optimize solid tumor treatment by converting tumor stroma from a barrier to a conduit for anti-cancer drugs and modifying the tumor microenvironment. The company has a strong intellectual property portfolio, including multiple patents and orphan drug designations, and is poised for Phase 3 trials in metastatic pancreatic ductal adenocarcinoma. Existing partnerships, such as with Qilu Pharmaceutical, support the broad applicability and promise of Certepetide.
The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock’s technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Lisata Therapeutics is a clinical-stage therapeutics company focused on developing novel solid tumor targeting and penetration technology with tumor microenvironment modifying properties. The company aims to enhance treatment benefits for solid tumors and similar diseases without additional side effects, utilizing a patient-friendly and pharmacoeconomically attractive approach. Lisata has a cash runway extending into the fourth quarter of 2026, no debt, and a seasoned management team with successful international drug development experience.
Average Trading Volume: 12,691
Technical Sentiment Signal: Sell
Current Market Cap: $21.58M
For an in-depth examination of LSTA stock, go to TipRanks’ Overview page.